Carmentix

Carmentix is a Singapore-based biotechnology company focused on developing a novel diagnostic tool to predict the risk of spontaneous preterm birth. By utilizing a proprietary proteomics-based biomarker discovery platform and machine learning, the company identifies molecular signatures in maternal blood that indicate a high risk of early delivery. Their lead product aims to provide clinicians with an early warning system, enabling timely interventions to improve neonatal outcomes. Carmentix operates with a research and development presence in Israel and has established clinical collaborations globally to validate its predictive tests.